Published in J Natl Cancer Inst on January 12, 2011
A Statewide Intervention to Reduce Use of Unproven or Ineffective Breast Cancer Care | NCT02831439
First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol (2015) 5.31
Bending the cost curve in cancer care. N Engl J Med (2011) 5.02
Cancer drugs in the United States: Justum Pretium--the just price. J Clin Oncol (2013) 4.25
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol (2015) 4.24
Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst (2012) 3.87
Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev (2013) 3.40
Cancer survivors: a booming population. Cancer Epidemiol Biomarkers Prev (2011) 3.33
Provision and discussion of survivorship care plans among cancer survivors: results of a nationally representative survey of oncologists and primary care physicians. J Clin Oncol (2014) 3.12
Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013. JAMA (2014) 3.03
Receipt of best care according to current quality of care measures and outcomes in men with prostate cancer. J Urol (2014) 2.67
The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer (2015) 2.63
What are cancer centers advertising to the public?: a content analysis. Ann Intern Med (2014) 2.50
Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol (2013) 2.39
An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer. Health Aff (Millwood) (2012) 2.16
Ensuring quality cancer care: a follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in America. Cancer (2011) 2.15
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol (2015) 1.88
Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev (2011) 1.82
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem (2012) 1.74
Regional variation in quality of prostate cancer care. J Urol (2013) 1.72
Clinical considerations for the development of biosimilars in oncology. MAbs (2015) 1.71
Medical oncologists' perceptions of financial incentives in cancer care. J Clin Oncol (2012) 1.69
High-cost imaging in elderly patients with stage IV cancer. J Natl Cancer Inst (2012) 1.63
Surgeon volume and elective resection for colon cancer: an analysis of outcomes and use of laparoscopy. J Am Coll Surg (2014) 1.61
Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely Campaign. JAMA Oncol (2015) 1.56
Low-Dose CT Lung Cancer Screening Practices and Attitudes among Primary Care Providers at an Academic Medical Center. Cancer Epidemiol Biomarkers Prev (2015) 1.52
Is dying in hospital better than home in incurable cancer and what factors influence this? A population-based study. BMC Med (2015) 1.52
Health care costs for patients with cancer at the end of life. J Oncol Pract (2012) 1.51
Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol (2016) 1.49
Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol (2012) 1.45
Breast Cancer 2012 - New Aspects. Geburtshilfe Frauenheilkd (2012) 1.45
Economic burden of cancer survivorship among adults in the United States. J Clin Oncol (2013) 1.41
Fragmentation in specialist care and stage III colon cancer. Cancer (2015) 1.41
Use of survivorship care plans in the United States: associations with survivorship care. J Natl Cancer Inst (2013) 1.38
Physical, emotional, and social health differences between posttreatment young adults with cancer and matched healthy controls. Cancer (2014) 1.34
Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park) (2013) 1.33
Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence. Am J Epidemiol (2013) 1.29
Acute hospital care is the chief driver of regional spending variation in Medicare patients with advanced cancer. Health Aff (Millwood) (2014) 1.28
Eliminating racial disparities in colorectal cancer in the real world: it took a village. J Clin Oncol (2013) 1.23
Understanding patients' attitudes toward communication about the cost of cancer care. J Oncol Pract (2012) 1.20
Is there such a thing as a cancer treatment that isn't worth its cost? Oncologist (2011) 1.18
Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. J Oncol Pract (2012) 1.18
Meeting the Healthy People 2020 Objectives to Reduce Cancer Mortality. Prev Chronic Dis (2015) 1.16
Did changes in drug reimbursement after the medicare modernization act affect chemotherapy prescribing? J Clin Oncol (2014) 1.15
Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin (2014) 1.15
Regional variation in spending and survival for older adults with advanced cancer. J Natl Cancer Inst (2013) 1.14
Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer. Springerplus (2014) 1.14
Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer (2014) 1.13
Association between travel distance and metastatic disease at diagnosis among patients with colon cancer. J Clin Oncol (2014) 1.09
State-level projections of cancer-related medical care costs: 2010 to 2020. Am J Manag Care (2012) 1.06
The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol (2017) 1.04
Gastric cancer stem cells: a novel therapeutic target. Cancer Lett (2013) 1.04
Opportunities for the primary prevention of colorectal cancer in the United States. Cancer Prev Res (Phila) (2011) 1.03
Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs (2012) 1.03
Patient experience and attitudes toward addressing the cost of breast cancer care. Oncologist (2014) 1.02
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. J Clin Oncol (2015) 1.02
Emerging roles of the microbiome in cancer. Carcinogenesis (2013) 1.00
Human endogenous retroviruses and cancer prevention: evidence and prospects. BMC Cancer (2013) 0.99
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J (2015) 0.98
A data mining approach for grouping and analyzing trajectories of care using claim data: the example of breast cancer. BMC Med Inform Decis Mak (2013) 0.98
Promoting state health department evidence-based cancer and chronic disease prevention: a multi-phase dissemination study with a cluster randomized trial component. Implement Sci (2013) 0.98
Costs and benefits of an organized fecal immunochemical test-based colorectal cancer screening program in the United States. Cancer (2014) 0.96
Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. J Clin Oncol (2015) 0.96
Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. Gastrointest Endosc (2013) 0.94
The influence of complications on the costs of complex cancer surgery. Cancer (2013) 0.94
Access to preventive health care for cancer survivors. Am J Prev Med (2013) 0.94
Gut microbiome and colorectal adenomas. Cancer J (2014) 0.94
Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain. Clinicoecon Outcomes Res (2013) 0.93
Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data. Br J Cancer (2015) 0.93
Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer. Oncologist (2014) 0.93
Inter-relationships between the economic and emotional consequences of colorectal cancer for patients and their families: a qualitative study. BMC Gastroenterol (2012) 0.93
Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer. J Clin Oncol (2015) 0.92
Out-of-pocket expenses and treatment choice for men with prostate cancer. Urology (2012) 0.92
Persistent cigarette smoking and other tobacco use after a tobacco-related cancer diagnosis. J Cancer Surviv (2012) 0.92
Value: The Next Frontier in Cancer Care. Oncologist (2016) 0.92
Primary care providers' perspectives on discontinuing prostate cancer screening. Cancer (2012) 0.92
When does an episode of care for cancer begin? Med Care (2013) 0.91
The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology. J Oncol Pract (2016) 0.91
Preventive evolutionary medicine of cancers. Evol Appl (2012) 0.91
Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis. J Oncol Pract (2012) 0.91
The Economic Burden of Breast Cancer in Korea from 2007-2010. Cancer Res Treat (2015) 0.90
Delivering High-Quality Cancer Care: The Critical Role of Quality Measurement. Healthc (Amst) (2014) 0.90
Flexible transbronchial optical frequency domain imaging smart needle for biopsy guidance. Biomed Opt Express (2012) 0.90
Lung cancer screening with low-dose computed tomography for primary care providers. Prim Care (2014) 0.90
ReCAP: Physician Experience and Attitudes Toward Addressing the Cost of Cancer Care. J Oncol Pract (2016) 0.90
Hospice shared-care saved medical expenditure and reduced the likelihood of intensive medical utilization among advanced cancer patients in Taiwan--a nationwide survey. Support Care Cancer (2014) 0.89
Costs of early adjuvant radiation therapy after radical prostatectomy: a decision analysis. Ann Oncol (2011) 0.89
Visit duration for outpatient physician office visits among patients with cancer. J Oncol Pract (2012) 0.89
"Just caring": can we afford the ethical and economic costs of circumventing cancer drug resistance? J Pers Med (2013) 0.89
Productivity savings from colorectal cancer prevention and control strategies. Am J Prev Med (2011) 0.88
Economic studies in colorectal cancer: challenges in measuring and comparing costs. J Natl Cancer Inst Monogr (2013) 0.88
Mass Spectrometry-Based (GeLC-MS/MS) Comparative Proteomic Analysis of Endoscopically (ePFT) Collected Pancreatic and Gastroduodenal Fluids. Clin Transl Gastroenterol (2012) 0.87
The strategies to control prostate cancer by chemoprevention approaches. Mutat Res (2014) 0.87
Overview of accountable care organizations for oncology specialists. J Oncol Pract (2013) 0.87
Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic. J Oncol Pract (2015) 0.87
Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy. J Clin Oncol (2015) 0.87
Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark. Clin Epidemiol (2013) 0.87
Annual patient time costs associated with medical care among cancer survivors in the United States. Med Care (2014) 0.86
National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011. Health Aff (Millwood) (2014) 0.86
Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS One (2015) 0.86
Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J (2013) 0.86
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care (2002) 21.63
Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst (2008) 7.85
American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol (2009) 6.77
The price tag on progress--chemotherapy for colorectal cancer. N Engl J Med (2004) 6.43
Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med (2009) 5.90
Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst (2008) 4.53
Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst (1995) 3.81
Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care (1999) 3.15
Current and future utilization of services from medical oncologists. J Clin Oncol (2008) 2.65
Cancer treatment cost in the United States: has the burden shifted over time? Cancer (2010) 2.10
Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer (1995) 1.95
Health insurance and spending among cancer patients. Health Aff (Millwood) (2003) 1.87
Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med (1999) 1.82
Cost of care for cancer in a health maintenance organization. Health Care Financ Rev (1997) 1.81
Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care (2009) 1.76
Estimation and projections of cancer prevalence from cancer registry data. Stat Med (2002) 1.75
Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020. Cancer Causes Control (2006) 1.64
Challenges in building disease-based national health accounts. Med Care (2009) 1.50
Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med Care (2005) 1.31
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med (2005) 16.70
Cancer statistics, 2004. CA Cancer J Clin (2004) 15.72
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst (2005) 8.36
Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst (2008) 7.85
Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst (2002) 6.87
Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst (2002) 6.64
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60
Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst (2008) 4.53
Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. Ann Intern Med (2004) 4.49
Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst (2004) 3.74
Estimating average annual per cent change in trend analysis. Stat Med (2009) 3.54
Barriers to colorectal cancer screening: a comparison of reports from primary care physicians and average-risk adults. Med Care (2005) 3.53
Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med (2009) 3.34
Health plan policies and programs for colorectal cancer screening: a national profile. Am J Manag Care (2004) 3.27
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst (2006) 3.19
Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst (2002) 3.04
Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev (2009) 3.04
Patient time costs associated with cancer care. J Natl Cancer Inst (2007) 2.90
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77
Surveying physicians: do components of the "Total Design Approach" to optimizing survey response rates apply to physicians? Med Care (2002) 2.68
Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol (2005) 2.67
Current and future utilization of services from medical oncologists. J Clin Oncol (2008) 2.65
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med (2010) 2.59
Estimating average annual percent change for disease rates without assuming constant change. Biometrics (2006) 2.51
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31
Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst (2012) 2.30
Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst (2008) 2.23
Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev (2007) 2.21
Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18
End-of-life care for lung cancer patients in the United States and Ontario. J Natl Cancer Inst (2011) 2.14
Comparability of segmented line regression models. Biometrics (2004) 2.12
Trends in esophageal adenocarcinoma incidence and mortality. Cancer (2012) 2.03
Age-conditional probabilities of developing cancer. Stat Med (2003) 2.03
Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst (2006) 2.01
Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med (2004) 1.97
Changing area socioeconomic patterns in U.S. cancer mortality, 1950-1998: Part I--All cancers among men. J Natl Cancer Inst (2002) 1.97
Estimating patient time costs associated with colorectal cancer care. Med Care (2005) 1.94
A national framework for cancer surveillance in the United States. Cancer Causes Control (2005) 1.89
Improving the quality of surveys of physicians and medical groups: a research agenda. Eval Health Prof (2012) 1.84
Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst (2008) 1.84
Care for the caregivers: a review of self-report instruments developed to measure the burden, needs, and quality of life of informal caregivers. J Pain Symptom Manage (2003) 1.84
Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst (2008) 1.83
A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making (2011) 1.77
Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care (2009) 1.76
Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol (2004) 1.75
Bias associated with self-report of prior screening mammography. Cancer Epidemiol Biomarkers Prev (2009) 1.75
Chapter 2: Birth-cohort-specific estimates of smoking behaviors for the U.S. population. Risk Anal (2012) 1.74
Projections of the costs associated with colorectal cancer care in the United States, 2000-2020. Health Econ (2008) 1.72
Clarifying differences in natural history between models of screening: the case of colorectal cancer. Med Decis Making (2011) 1.71
SELECTING THE NUMBER OF CHANGE-POINTS IN SEGMENTED LINE REGRESSION. Stat Sin (2009) 1.69
Trends in colorectal cancer test use in the medicare population, 1998-2005. Am J Prev Med (2009) 1.68
Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020. Cancer Causes Control (2006) 1.64
Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care (2009) 1.62
Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. Ann Intern Med (2013) 1.62
Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr (2006) 1.61
Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol (2007) 1.54
Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol (2002) 1.52
Modeling the dissemination of mammography in the United States. Cancer Causes Control (2005) 1.52
Whatever happened to clinical breast examinations? Am J Prev Med (2003) 1.47
Next generation analytic tools for large scale genetic epidemiology studies of complex diseases. Genet Epidemiol (2011) 1.47
Are physicians' recommendations for colorectal cancer screening guideline-consistent? J Gen Intern Med (2010) 1.44
A new method of predicting US and state-level cancer mortality counts for the current calendar year. CA Cancer J Clin (2004) 1.42
Economic burden of cancer survivorship among adults in the United States. J Clin Oncol (2013) 1.41
Interventions to improve follow-up of abnormal findings in cancer screening. Cancer (2004) 1.41
Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med Care (2008) 1.37
Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer (2013) 1.36
Cervical cancer screening in the United States and the Netherlands: a tale of two countries. Milbank Q (2012) 1.35
A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin (2007) 1.33
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med (2014) 1.32
Realizing the promise of breast cancer screening: clinical follow-up after abnormal screening among Black women. Prev Med (2003) 1.32
Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death. Risk Anal (2012) 1.31
Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monogr (2006) 1.30
Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence. Am J Epidemiol (2013) 1.29
Too much of a good thing? Physician practices and patient willingness for less frequent pap test screening intervals. Med Care (2010) 1.27
Racial differences in the receipt of bowel surveillance following potentially curative colorectal cancer surgery. Health Serv Res (2003) 1.27
Burden of illness in adult survivors of childhood cancers: findings from a population-based national sample. Cancer (2010) 1.26
Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status. J Gen Intern Med (2005) 1.25
Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis. J Natl Cancer Inst Monogr (2006) 1.23
Breast cancer survivors in the United States: geographic variability and time trends, 2005-2015. Cancer (2009) 1.19
Dynamic microsimulation models for health outcomes: a review. Med Decis Making (2010) 1.18
Medical costs and productivity losses of cancer survivors--United States, 2008-2011. MMWR Morb Mortal Wkly Rep (2014) 1.18
Cure fraction estimation from the mixture cure models for grouped survival data. Stat Med (2004) 1.18
What proportion of breast cancers are detected by mammography in the United States? Cancer Detect Prev (2007) 1.16
Secular trends in colon and rectal cancer relative survival. J Natl Cancer Inst (2013) 1.16
A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. J Natl Cancer Inst Monogr (2006) 1.15
Improving the concordance of mammography assessment and management recommendations. Radiology (2006) 1.15
Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality. J Natl Cancer Inst Monogr (2006) 1.15
Regional variation in spending and survival for older adults with advanced cancer. J Natl Cancer Inst (2013) 1.14
Predicting US- and state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence. Cancer (2012) 1.14